1. Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs
Marisa Actis,Brandon Smart,Stanley Nithianantham,Jun J Yang,Gisele Nishiguchi,Charles G Mullighan,Jaeki Min,Jeremy Hunt,Dylan Maxwell,Yunchao Chang,Anand Mayasundari,Zoran Rankovic,Marcus Fischer,Lisa J Alcock,Jamie A Jarusiewicz ACS Med Chem Lett . 2022 Feb 21;13(3):475-482. doi: 10.1021/acsmedchemlett.1c00650.
Aberrant activation of the JAK-STAT signaling pathway has been implicated in the pathogenesis of a range of hematological malignancies and autoimmune disorders. Here we describe the design, synthesis, and characterization of JAK2/3 PROTACs utilizing a phenyl glutarimide (PG) ligand as the cereblon (CRBN) recruiter. SJ10542 displayed high selectivity over GSPT1 and other members of the JAK family and potency in patient-derived ALL cells containing both JAK2 fusions and CRLF2 rearrangements.